Jeffrey Cummings1, Paul Aisen2, Cynthia Lemere3, Alireza Atri4,5, Marwan Sabbagh6, Stephen Salloway7
Affiliation and address for correspondence
1 Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV), Las Vegas, NV, USA
2 University of Southern California, San Diego, CA, USA
3 Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
4 Banner Sun Health Research Institute, Banner Health, Sun City, AZ, USA
5 Center for Brain/Mind Medicine, Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
6 Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA
7 Butler Hospital and Brown University, Providence, RI, USA
Correspondence: Jeffrey Cummings, jcummings@cnsinnovations.com, Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV), Las Vegas, NV, USA
adukanumab, FDA, badania kliniczne, przeciwciała monoklonalne, lecanemab, donanemab, gantenerumab
